|
Source
Breast Cancer Update Patterns of Care 2005;2(3).
Purpose
This publication reports the results of a Breast Cancer Patterns of Care survey,
completed in August and September of 2005 by 45 breast cancer clinical investigators
and 100 randomly selected United States-based medical oncologists,
designed to compare how these two groups of medical oncologists integrate
clinical research results into their practices. The adjuvant endocrine therapy
section of this publication is reviewed here.
Results
SELECT PUBLICATIONS
Coombes RC et al; Intergroup Exemestane Study. A randomized trial of exemestane after
two to three years of tamoxifen therapy in postmenopausal women with primary breast
cancer. N Engl J Med 2004;350(11):1081-92. Abstract
Davidson N et al. Chemoendocrine therapy for premenopausal women with axillary
lymph node-positive, steroid hormone receptor-positive breast cancer: Results from
INT 0101 (E5188). J Clin Oncol 2005;23(25):5973-82. Abstract
Gnant M et al. Zoledronic acid effectively counteracts cancer treatment induced bone
loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine
treatment with goserelin plus anastrozole versus goserelin plus tamoxifen — Bone
density subprotocol results of a randomized multicenter trial (ABCSG-12). San Antonio
Breast Cancer Symposium 2004;Abstract 6.
Goss PE et al. NCIC CTG MA17: Disease free survival according to estrogen receptor
and progesterone receptor status of the primary tumor. San Antonio Breast Cancer
Symposium 2005;Abstract 2042.
Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years
of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802.
Abstract
Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone
or in Combination) trial after completion of 5 years’ adjuvant treatment for breast
cancer. Lancet 2005;365(9453):60-2. Abstract
Ingle JN et al. Analysis of duration of letrozole extended adjuvant therapy as measured
by hazard ratios of disease recurrence over time for patients on NCIC CTG MA17. San Antonio Breast Cancer Symposium 2005;Abstract 17.
Jakesz R et al. Switching of postmenopausal women with endocrine-responsive early
breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: Combined results of
ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366(9484):455-62. Abstract
Jakesz R et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in
postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis
of ABCSG Trial 8. San Antonio Breast Cancer Symposium 2005;Abstract 13.
Jakesz R et al; ABCSG and the GABG. Benefits of switching postmenopausal women with
hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen:
Combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95
Trial. San Antonio Breast Cancer Symposium 2004;Abstract 2.
Jakesz R et al; Austrian Breast and Colorectal Cancer Study Group Trial 5. Randomized
adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and
fluorouracil: Evidence for the superiority of treatment with endocrine blockade in
premenopausal patients with hormone-responsive breast cancer — Austrian Breast and
Colorectal Cancer Study Group Trial 5. J Clin Oncol 2002;20(24):4621-7. Abstract
Kudachadkar R, O’Regan RM. Aromatase inhibitors as adjuvant therapy for postmenopausal
patients with early stage breast cancer. CA Cancer J Clin 2005;55(3):145-63. Abstract
Mouridsen HT, Robert NJ. The role of aromatase inhibitors as adjuvant therapy for early
breast cancer in postmenopausal women. Eur J Cancer 2005;41(12):1678-89. Abstract
Thürlimann B. BIG1-98: A prospective randomized double-blind double-dummy phase
III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal
women with receptor-positive breast cancer. Breast 2005a;14(Suppl 1):3;S4.
Thürlimann B et al. BIG1-98: Randomized double-blind phase III study to evaluate letrozole
(L) vs tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women
with receptor-positive breast cancer. Presentation. ASCO 2005;Abstract 511.
Winer EP et al. American Society of Clinical Oncology technology assessment on the
use of aromatase inhibitors as adjuvant therapy for postmenopausal women with
hormone receptor-positive breast cancer: Status Report 2004. J Clin Oncol 2005;23(3):619-29. Abstract
|
